Journal of Hepatology ’s Post

Check our July issue! This month's cover features the article “Sex and ethnic disparities in hepatitis B evaluation and treatment across the world” by Sahith K., Daniel Q. Huang et al. (https://bit.ly/4c80VHo) Full issue here: https://bit.ly/2LXwYxk EASL | The Home of Hepatology

Loss of the ciliary gene Pkd1l1 contributes to biliary atresia pathology Biliary atresia, a pediatric cholangiopathy, is the most common indication for pediatric liver transplantation worldwide. Its etiology is multifactorial, occurring in isolation or with congenital anomalies. This study, shows that PKD1L1 gene variants, identified in syndromic cases, contribute to biliary atresia pathology. Pkd1l1-deficient mice exhibited congenital anomalies, including malrotation and heterotaxy, ductular reaction, periportal fibrosis, and hypertrophic and fibrotic extrahepatic bile ducts with delayed biliary drainage. Moreover, reduced primary cilia and altered ciliogenesis gene expression were observed in cholangiocytes. Full text here: https://lnkd.in/d72hdwg9 EASL | The Home of Hepatology

WHAT IS YOUR DIAGNOSIS ❓ A 27-year old man is admitted to the hospital with fever, jaundice, elevated transaminses (> 2000 IU/L), LDH (> 1000 IU/L) and progressive anemia. 👨🔬On physical examination splenomegaly. - Viral hepatitis serologies were negative. - A liver biopsy was performed. 🤔What is your diagnosis? 1️⃣ Adult-onset Still’s disease 2️⃣ Epstein-Barr virus infection 3️⃣ Drug-induced liver injury 4️⃣ Hepatosplenic T-cell lymphoma Full case here👉https://lnkd.in/dnWd5NpT EASL | The Home of Hepatology

How to predict decompensation and mortality in patients with alcohol-related liver disease (ALD)? Patients with ALD face significant risks of disease progression and adverse outcomes. Liver stiffness measurement (LSM) is recommended for prognostication and monitoring. This study, shows that LSM is useful for ALD prognosis. Elevated baseline LSM (>10 kPa) was linked to a 19-fold increased risk of decompensation. LSM changes over two years correlated with decompensation and death, with higher LSM indicating worse outcomes. #OpenAccess here: https://lnkd.in/dQmv4c8a Maja Thiele Aleksander Krag EASL | The Home of Hepatology

Developing and validating clinical prediction models in hepatology – An overview for clinicians Prediction models are everywhere in clinical medicine. We use them to assign a diagnosis or a prognosis, and there have been continuous efforts to develop better prediction models. It is important to understand the fundamentals of prediction modelling, thus, we herein describe nine steps to develop and validate a clinical prediction model with the intention of implementing it in clinical practice: Determine if there is a need for a new prediction model; define the purpose and intended use of the model; assess the quality and quantity of the data you wish to develop the model on; develop the model using sound statistical methods; generate risk predictions on the probability scale (0-100%); evaluate the performance of the model in terms of discrimination, calibration, and clinical utility; validate the model using bootstrapping to correct for the apparent optimism in performance; validate the model on external datasets to assess the generalisability and transportability of the model; and finally publish the model so that it can be implemented or validated by others. @OpenAccess here: https://lnkd.in/d88G6f4b Rickard Strandberg EASL | The Home of Hepatology

Novel animal model of extrahepatic cholangiocarcinoma The PTEN-AKT pathway is frequently disrupted in extrahepatic cholangiocarcinoma (eCCA). This study, shows that conditional knockout mice with targeted deletion of the Pten gene in extrahepatic biliary epithelial cells replicate the progression from sclerosing cholangitis-like lesions to dysplasia, ultimately leading to eCCA. Notably, Trp53 inactivation hastened disease progression. Both genetic and pharmacological strategies aimed at reducing AURKA expression, which is elevated in both human and mouse eCCA, effectively mitigated disease progression. Full text here: https://lnkd.in/dDgT-M9b EASL | The Home of Hepatology

Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting Patients with cirrhosis are prone to developing acute kidney injury (AKI), a complication associated with a markedly increased in-hospital morbidity and mortality, along with a risk of progression to chronic kidney disease. Whereas patients with cirrhosis are at increased risk of developing any phenotype of AKI, hepatorenal syndrome (HRS), a specific form of AKI (HRS-AKI) in patients with advanced cirrhosis and ascites, carries an especially high mortality risk. Early recognition of HRS-AKI is crucial since administration of splanchnic vasoconstrictors may reverse the AKI and serve as a bridge to liver transplantation, the only curative option. In 2023, a joint meeting of the International Club of Ascites (ICA) and the Acute Disease Quality Initiative (ADQI) was convened to develop new diagnostic criteria for HRS-AKI, to provide graded recommendations for the work-up, management and post-discharge follow-up of patients with cirrhosis and AKI, and to highlight priorities for further research. #OpenAccess here: https://lnkd.in/d8ghCUGy François Durand EASL | The Home of Hepatology

Insights from the first prospective study of stereotactic ablative radiotherapy (SABR) in oligometastatic HCC Stereotactic ablative radiotherapy (SABR) represents a non-invasive treatment option for patients with oligometastatic disease (OMD). This phase II study, underscores SABR's viability and safety in treating oligometastatic HCC, showcasing exceptional local tumor control and enhanced survival outcomes while preserving patients' quality of life, irrespective of metastatic site. Patients with later-stage OMD arising from a controlled primary and showing lower alpha-fetoprotein levels experienced superior survival benefits. Full text here: https://lnkd.in/dTRjnJd2 EASL | The Home of Hepatology

HEPATOLOGY SNAPSHOT Animal hepacivirus models for hepatitis C virus immune responses and pathology Find it here: https://lnkd.in/di5fBEMa Matthew Kennedy Sonja Fernbach Troels K H Scheel EASL | The Home of Hepatology

🌟 We are thrilled to announce Prof. Vlad Ratziu as the new Editor-in-Chief of the Journal of Hepatology , starting January 2025! Prof. Ratziu, a distinguished professor at Sorbonne University and researcher at the Institute for Cardiometabolism and Nutrition (ICAN) in Paris, brings exceptional expertise and vision to our esteemed journal. Joining him are esteemed hepatology leaders: - Annalisa Berzigotti and Frank Tacke as Deputy Editors - Tom H. Karlsen, Lorenza Rimassa, and Heiner Wedemeyer as Co-Editors - Philip Newsome as Senior Editor We are excited to collaborate with the new editorial team and look forward to their contributions in advancing liver research and innovation. More info: https://lnkd.in/euG97b3q EASL | The Home of Hepatology